Lisa Jarvis, Columnist

Progress on HPV Vaccines Is Too Important to Lose

Thanks to the pandemic and various legal challenges, HPV vaccination rates have flatlined.

September 26, 2022 at 1:00 PM UTC

Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News.

Not controversial.
Photographer: Bloomberg

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

HPV vaccinations among teens in the US dropped precipitously during the early pandemic, a disappointing reversal for shots that can prevent more than 33,000 cases of cancer each year. Worse, efforts to get vaccinations back on track could be stymied by legal challenges.

We can’t let a decade worth of slow and steady progress in HPV vaccinations be lost.